Key Takeaways & Executive Findings
- •• Mediterranean and plant-based diets are cost-effective for preventing cardiovascular disease and type 2 diabetes, with ICERs below $50,000/QALY. • Nutritional interventions yield net cost savings in high-risk populations by reducing hospitalizations and medication use. • Economic modeling demonstrates long-term health benefits and cost-effectiveness across diverse willingness-to-pay thresholds. • Findings support policy and clinical integration of nutritional counseling and food-based interventions for chronic disease prevention.
Abstract
Background: Nutritional interventions are increasingly recognized as cost-effective strategies for preventing chronic diseases, yet comprehensive economic evaluations remain scarce. This study aims to assess the cost-effectiveness of various nutritional programs targeting cardiovascular disease and type 2 diabetes prevention. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials and economic modeling studies. A Markov model simulated long-term health outcomes and costs from a societal perspective. Incremental cost-effectiveness ratios (ICERs) were calculated for each intervention compared with usual care. Results: The Mediterranean diet and plant-based dietary patterns demonstrated the most favorable ICERs, with values below $50,000 per quality-adjusted life year (QALY) gained. Cost savings were observed in high-risk populations due to reduced hospitalization and medication use. Sensitivity analyses confirmed robustness across varying willingness-to-pay thresholds. Conclusions: Nutritional interventions, particularly Mediterranean and plant-based diets, are cost-effective for chronic disease prevention, supporting their integration into public health policies and clinical practice.
1. Introduction
Chronic diseases such as cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) impose a substantial burden on healthcare systems worldwide, accounting for a significant proportion of morbidity, mortality, and healthcare expenditures. Nutritional factors are among the leading modifiable risk factors for these conditions, with unhealthy dietary patterns contributing to the development of obesity, hypertension, dyslipidemia, and insulin resistance. Consequently, there is growing interest in implementing nutritional interventions as a primary prevention strategy. However, the economic implications of such interventions are not fully understood, and decision-makers require robust cost-effectiveness evidence to allocate limited resources efficiently.
Previous economic evaluations have examined specific dietary approaches, such as the Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH), and plant-based diets, but results have been heterogeneous due to differences in study design, populations, and modeling assumptions. Moreover, many analyses have focused on single interventions without comparing multiple strategies within a unified framework. This study aims to fill this gap by conducting a comprehensive cost-effectiveness analysis of several nutritional interventions for the prevention of CVD and T2DM, using a consistent methodology and a societal perspective. By synthesizing clinical evidence and economic modeling, we provide actionable insights for policymakers, clinicians, and public health practitioners.
Loading authentic research manuscript (Pages 1–5)...
John A. Smith, Emily R. Johnson, Michael T. Brown, Sarah L. Davis (2026). Cost-Effectiveness Analysis of Nutritional Interventions for Chronic Disease Prevention. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-0100-1
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the cost-effectiveness of nutritional interventions for chronic disease prevention?
The study found that Mediterranean and plant-based diets are cost-effective, with incremental cost-effectiveness ratios below $50,000 per quality-adjusted life year gained, and can even result in cost savings in high-risk populations.
Which nutritional interventions were compared in the analysis?
The analysis compared several dietary patterns, including the Mediterranean diet, DASH diet, plant-based diets, and low-fat diets, against usual care for preventing cardiovascular disease and type 2 diabetes.
How was the cost-effectiveness analysis conducted?
A systematic review and meta-analysis of clinical trials informed a Markov model that simulated long-term health outcomes and costs from a societal perspective. Incremental cost-effectiveness ratios were calculated for each intervention.
What are the implications for public health policy?
The findings support the integration of nutritional counseling and food-based interventions into public health programs and clinical practice as cost-effective strategies for reducing the burden of chronic diseases.
Are the results robust across different willingness-to-pay thresholds?
Yes, sensitivity analyses showed that the conclusions were robust across a range of willingness-to-pay thresholds, indicating high confidence in the cost-effectiveness of the leading interventions.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.